HERON THERAPEUTICS, INC. /DE/ Proceeds from (Repayments of) Notes Payable
HERON THERAPEUTICS, INC. /DE/ (HRTX) reported Proceeds from (Repayments of) Notes Payable of $24.35 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepaymentsOfNotesPayable · last filed 2025-02-27
- HERON THERAPEUTICS, INC. /DE/ proceeds from (repayments of) notes payable for the quarter ending 2023-12-31 was $0.00.
- HERON THERAPEUTICS, INC. /DE/ proceeds from (repayments of) notes payable for fiscal 2023 was $24.35M.
| Period end | Proceeds from (Repayments of) Notes Payable 3 month | Proceeds from (Repayments of) Notes Payable 9 month | Proceeds from (Repayments of) Notes Payable 12 month |
|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $24.35M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $24.35M 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Xilio Therapeutics, Inc. (XLO) | United States | $0.052B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| Lite Strategy, Inc. (LITS) | United States | $0.049B |